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ABSTRACT
Purpose To develop and evaluate a tool for the qualitative pre-
diction of human oral bioavailability (Fhuman) from animal oral
bioavailability (Fanimal) data employing ROC analysis and to identify
the optimal thresholds for such predictions.
Methods A dataset of 184 compounds with known Fhuman and
Fanimal in at least one species (mouse, rat, dog and non-human
primates (NHP)) was employed. A binary classification model for
Fhuman was built by setting a threshold for high/low Fhuman at 50%.
The thresholds for high/low Fanimal were varied from 0 to 100 to
generate the ROC curves. Optimal thresholds were derived from
‘cost analysis’ and the outcomes with respect to false negative and
false positive predictions were analyzed against the BDDCS class
distributions.
Results We successfully built ROC curves for the combined
dataset and per individual species. Optimal Fanimal thresholds were
found to be 67% (mouse), 22% (rat), 58% (dog), 35% (NHP)
and 47% (combined dataset). No significant trends were ob-
served when sub-categorizing the outcomes by the BDDCS.
Conclusions Fanimal can predict high/low Fhuman with adequate sen-
sitivity and specificity. This methodology and associated thresholds can
be employed as part of decisions related to planning necessary studies
during development of new drug candidates and lead selection.
KEY WORDS BDDCS . interspecies . oral bioavailability .
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ABBREVIATIONS
AUC Area under the ROC curve
BCS Biopharmaceutical classification system
BDDCS Biopharmaceutical drug disposition classification
system
F Oral bioavailability
fa Fraction of the dose absorbed in the gastrointes-
tinal tract
Fanimal Oral bioavailability in animals/species
FG Fraction of the dose absorbed that escapes gut
wall first pass metabolism
FH Fraction of the dose absorbed that escapes hepatic
first pass metabolism







NPV Negative predictive value
PPV Positive predictive value
QSAR Quantitative structure-activity relationship
ROC Receiver operating characteristics
tA Animal, high/low oral bioavailability threshold
tH Human, high/low oral bioavailability threshold
TN True negative
TNR True negative rate
TP True positive
TPR True positive rate
US-FDA United States Food and Drug Administration
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INTRODUCTION
Oral bioavailability (F ) is considered a key parameter during
drug development. It can be defined as the fraction of the dose
administered orally that reaches systemic circulation, as its
unchanged form, which becomes available at its intended site
of action to produce the desired therapeutic effect. Even
though the latter is difficult to measure, it is usually assumed
that the amount of drug at the site of action is proportional to
the amount of drug in plasma/blood. Oral bioavailability is
dependent upon the fraction of dose that is absorbed in the
gastrointestinal (GI) tract (f a), as well as the fraction that
escapes first pass metabolism in both the GI tract and the
liver, FG and FH, respectively (Eq. 1)(1,2).
F ¼ f a  FG  FH ð1Þ
Despite its importance, the information regarding oral
drug bioavailability is not always available during the devel-
opment stages, as it usually requires the administration of an
intravenous (iv ) dose as a reference. However, due to safety
and solubility reasons the iv dose is not always available;
therefore, drug oral bioavailability is generally unknown until
later stages in the development process. In addition, low oral
bioavailability is generally associated with higher inter indi-
vidual variability (3).
It is a common practice during drug development to em-
ploy animal models for the in vivo determination of safety,
efficacy and pharmacokinetic properties of a drug candidate
(1). The main goal of such studies is to predict drug’s
behaviour in humans/man based on animal data. The rela-
tionship between the animal models and human oral drug
bioavailability has been studied on several occasions. One of
the first attempts to investigate this relationship was performed
by Sietsema in 1989, where a poor correlation was found
between animal (rodents, dogs and non-human primates
(NHP)) and human oral bioavailability (4). The lack of corre-
lation could be explained by the interspecies differences in the
factors governing oral bioavailability such as morpho-
physiological differences in GI tract, abundance of trans-
porters and metabolic enzymes and their regional distribu-
tion, given that physicochemical properties are inherent to
the drug and/or formulation (1,4–11). Nonetheless, cor-
relations have been established for intestinal permeability
and/or the fraction of dose absorbed between humans
and preclinical species, in particular for rat and NHP
(10,12–14), suggesting that for those particular species,
bioavailability differences may rely on the metabolic
component.
Based on Sietsema (1989) data, Grass and Sinko (15) plot-
ted the relationship between animal and human oral bioavail-
ability. The plot was similar to a scatter plot and therefore no
trends were observed between animal and human bioavail-
ability. However, issues were found with regards to the num-
ber of data points in the plot as compared to the original
publication from Sietsema (1989), in addition species defini-
tions and the fact of the publication was based on data from
1989 were suggestive that a new dataset was needed in order
to perform a comprehensive analysis of the relationship be-
tween animal and human oral bioavailability. A recent study
by Musther and co-workers (16), addressed those needs by
introducing a more comprehensive and updated dataset and
the correlations between animal and human oral bioavailabil-
ity were investigated. Their results were in agreement with the
analysis performed in the past by several groups (4,9,
13,17,18). Amongst the species studied, NHP showed the stron-
gest correlation with human, followed by poor correlations for
dog, rat and mouse. However the large prediction intervals
suggest that a pointwise correlation between human and pre-
clinical species is not plausible. In terms of qualitative predic-
tions, the study showed that mouse, rat and NHP underpredict
human bioavailability. More interestingly, the median of the
ratio between animal and human bioavailability was close to
unity, however the large intervals for the median ratio suggest
that these results should be treated carefully. Despite the sug-
gested lack of predictability of human oral bioavailability from
preclinical species, the models are still employed during drug
development. The information gathered from oral bioavailabil-
ity studies in animal models is employed as part of the decision
making process of whether to continue or not with the develop-
ment of any particular drug (19,20).
Marketed drugs and drug candidates can be classified
according to extent of metabolism by means of the
Biopharmaceutics Drug Disposition System (BDDCS) (21).
Similarly to the Biopharmaceutics Classification System
(BCS) (22), the BDDCS divides the compounds into four
classes based on their aqueous solubility and permeability.
However, the main difference between the two systems is the
permeability component. In the BCS, permeability relates to
intestinal permeability rate and the extent of absorption,
whereas with the BDDCS permeability relates to the perme-
ability rate in the intestine and/or liver, which was found to be
correlated with the extent of metabolism (21,23,24). The
BDDCS defines a highly soluble compound as a compound
whose highest regulatory approved strength is able to dissolve
in 250 mL (or less) of water throughout a pH range of 1 to
7.5 at 37°C. Likewise, the BDDCS defines highly permeable
compounds as compounds where 70% or more of the admin-
istered oral dose is metabolized. A compound is considered
poorly metabolized if 50% ormore of the administered dose is
excreted in the urine or bile in its unchanged form (25–28).
Thus, BDDCS Class 1 compounds are highly soluble and
highly metabolized, Class 2 compounds are poorly soluble
and highly metabolized, Class 3 compounds are highly soluble
and poorly metabolized and Class 4 compounds are poorly
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soluble and poorly metabolized. In addition, it has been
suggested that BDDCS class can be useful to estimate the
impact of intestinal transporters in drug absorption and me-
tabolism as well as propose possible food effect and clinically
relevant drug-drug interactions (21,25–29).
A model can be evaluated based upon its ability to correctly
predict any particular outcome, where the prediction perfor-
mance of a binary classification model can be evaluated by
means of Receiver Operating Characteristic (ROC) analysis.
The ROC space consists of a plot of the False Positive Rate
(FPR) as a function of the true positive rate (TPR). A binary
classification is represented by a single point in the ROC space,
where a perfect classification will have a FPR of 0 and a TPR of
1. Likewise, a continuous system can be represented by curve in
the ROC space and the area under the ROC curve (AUC) can
be employed as a measure of the performance of the predictions
made from the classification system or model. An AUC of 1
corresponds to a perfect classification/prediction and an AUC of
0.5 corresponds to a random classification/prediction (30–32).
In the present study, we introduce a new model for the
categorical prediction of human oral bioavailability, stated as
low or high, from animal data by employing a threshold deci-
sion tool based upon ROC analysis. Oral bioavailability for
more than 180 compounds was analysed in different preclinical
species to generate animal oral bioavailability thresholds that
can be employed for the qualitative prediction of human oral
bioavailability. Furthermore, the relationships between the
resulting classifications were compared with the BDDCS classi-
fication of the compounds employed for the analysis.
MATERIALS AND METHODS
Dataset Employed
A total of 184 different compounds with reported oral bio-
availability in both human and preclinical species, namely
mouse, rat, dog and NHP, were employed in this study. The
oral bioavailability values for the compounds were collated
from the literature by Musther and co-workers, as described
elsewhere (16).
Binary Classification and ROC Analysis
A binary classification model was implemented by
establishing a threshold (tH ) for high and low human
bioavailability at 50% (Eq. 2). A positive outcome (high
Fhuman ) was defined when Fhuman was greater or equal
than 50%, while a negative outcome (low Fhuman ) oc-
curred when Fhuman was less than 50%.
Fhuman ¼ high; if F human ≥ tHlow; if F human < tH

ð2Þ
In a similar fashion, Eq. 2 was modified to classify high and
low Fanimal, by setting up a threshold for animal oral bioavail-
ability (t A) as per Eq. 3.
Fanimal; species ¼ high; if F animal; species ≥ tAlow; if F animal; species< tA

ð3Þ
Thus for Fanimal based predictions, false positives (FP) were
compounds with high Fanimal and low Fhuman, and false nega-
tives (FN) were compounds with low Fanimal and high Fhuman
(Fig. 1). If both Fanimal and Fhuman were high, the compound
was classified as a true positive (TP), similarly if both Fanimal
and Fhuman were low, the compound was considered as a true
negative (TN). The predictions based on the animal data
analysis for bioavailability were evaluated by calculating its
sensitivity, specificity, positive predictive value (PPV) and neg-
ative predictive value (NPV) for the determined animal
thresholds (tA), as shown in Table I.
All the statistical analysis and the ROC curve generation
were implemented with Matlab® 2012a and its statistical
toolbox (The MathWorks Inc., Natick, MA, USA). The con-
struction of the ROC curves, for the overall dataset and by
species, was achieved by varying t A form 0 to 100 and record-
ing the error rates (Table I) for each threshold. The overall (all
the species combined) ROC curve was constructed by consid-
ering all the datapoints within the dataset, including the
compounds with Fanimal values in more than one preclinical
Fig. 1 Threshold based predictions of human oral bioavailability from animal
data. FN, False negatives; TP, True positives; TN, True negatives; FP, False
positive; tA, Animal high/low bioavailability threshold; tH, human high/low
bioavailability threshold.
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species. In addition, a bootstrap random resampling (n=
10000) ,with replacement, was performed for the determina-
tion of the average ROC curves and the bias corrected con-
fidence intervals for the resulting AUC, sensitivity and speci-
ficity. The curves were averaged by threshold averaging func-
tion within Matlab®. The significance of the differences be-
tween the resulting AUCs (for each species and the overall
dataset) and the random classification (AUC=0.5) were cal-
culated by the non-parametric Mann-Whitney U test. Deter-
minations of the optimal thresholds for the averaged ROC
curves were calculated as the interception of a line of slope, S
(Eq. 4), with the averaged ROC curve.
S ¼ cost FPð Þ−cost TNð Þ




Where, cost(FP) and cost(FN) are the costs of FP and FN,
respectively; cost(TN) and cost(TP) are the costs of TN and TP,
respectively; N and P , are the number of positives and negatives
values based on Fhuman data (32). The net costs for TN and TP
were assumed to be 0, initially the net costs for FP and FN were
assumed equal. Subsequently, the cost ratio between FP and FN
was varied in order to evaluate the impact of the cost assumptions
on the determination of the optimal threshold points.
For rat, dog and NHP, alternative thresholds were deter-
mined by visually comparing the relationship between animal
threshold (tA) versus its resulting sensitivity and specificity; the
closest points to the intersection lines between the latter two
were considered as alternative thresholds. New thresholds
were compared against the optimal thresholds derived from
cost analysis employing Youden’s index ( J) (Eq. 5), where the
maximum value for J is 1 for a perfect classification, whereas
the minimum value is 0 for a threshold with no predictive
power (33).
J ¼ sensitivityþ specificity− 1 ð5Þ
An additional ROC analysis was performed for the com-
pounds in the dataset whose Fhuman values were ≤20% (very
low oral bioavailability) in the overall dataset, and for these
compounds the human threshold for high/low oral bioavail-
ability was set up at 10%. The analysis was conducted using
rat, dog and NHP data and the significance of the AUC and
determination of optimal thresholds was performed, as
described above (Eq. 4).
BDDCS Classification
The BDDCS classification for 155 of the compounds in the
current study was obtained from the dataset published by
Benet, and co-workers (34), while for the remaining com-
pounds, a provisional BDDCS classification was given. All
individual drugs used for the analysis and their allocated
BDDCS classification are listed in Tables SI and SII of the
Supplementary Material. For the classification, the extent of
metabolism and/or percentage of the dose excreted
unchanged in the urine and/or bile was collated from the
literature. With regards to solubility determination, for US-
FDA approved drugs, the maximum dose strength was taken
from the label, when possible; otherwise the maximum dose
strength was extracted from published data. Aqueous solubil-
ity values were taken from published data when possible,
otherwise the “Mass Solubility” value within SciFinder®
chemical properties was employed (35). High/low solubility
was assigned using Eq. 6, where Dn is the dose number, Dmax
is the maximum dose strength (mg) and Cs is the aqueous
solubility (mg/mL). High solubility was assigned to com-
pounds with Dn equal or greater than 1, while low solubility





Class distribution was then compared within each of the
threshold-based outcome groups (i.e. true positives (TP), true
negatives (TN), false positives (FP) and false negatives (FN)) for
the rat, dog and NHP. Significance of the difference between
the BDDCS class distribution within each of the out-
come groups (i.e. TP, TN, FP, FN) were evaluated by
visual inspection of the plots and by employing Fisher’s
exact test implemented in the R statistics Package
(http://www.r-project.org/).
RESULTS
The analysed dataset consisted in total of 318 data points for
animal and human oral bioavailability divided in 30, 122, 125
and 41 pairwise correlations between mouse, rat, dog and
NHP with human oral bioavailability, respectively (Fig. 2a).
For some of the compounds in the dataset oral bioavailability
Table I Definitions and Formulae for the Evaluation of the Binary Classification
System
Parameter Formula Probability
Sensitivity or TPR TP
TPþFN P [ high Fanimal| high Fhuman]
Specificity or TNR TN
TNþFP P [ low Fanimal| low Fhuman]
PPV TP
TPþFP P [ high Fhuman | high Fanimal]
NPV TN
TNþFN P [low Fhuman | low Fanimal]
FPR 1−TNR P [ high Fanimal| low Fhuman]
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values were available for more than one species as shown in
Fig. 2b for rat, dog and NHP.
The summary of resulting ROC curves for the total dataset
of 318 Fanimal values and per individual species are shown in
Table II. Combination of all Fanimal values resulted in a
smooth ROC curve with an AUC around 0.8 (Fig. 3). A
similar outcome was observed employing individual dog and
rat data (Fig. 4b, c) with ROC curve AUC for dog data slightly
higher than for the rat (0.8 and 0.7, respectively). In contrast,
ROC curves generated for mouse and NHP resulted in a step-
like curve rather than a smooth curve (Fig. 4a, d), primarily
attributed to the limited number of data points employed in
their construction. However, the AUC values of the latter
ROC curves were higher than for the overall dataset and
the rest of the species. Interestingly, NHP showed an AUC
value close to the unity (0.96). With regards to the significance
tests for the above AUCs - all the species combined and by
species- showed high significance levels compared to the ran-
dom classification (AUC=0.5) yet for mouse data, p-value was
slightly higher than for the rest of the species.
The ‘cost analysis’ determinations of the optimal Fanimal
thresholds are summarized in Tables III and IV For the
overall dataset, threshold was 47%, in agreement with the
50% value employed for the human bioavailability threshold
with resulting specificity and sensitivity of 0.82 and 0.66,
respectively. A similar situation occurred for dog data, though
the threshold was slightly higher than for the overall dataset,
whereas specificity and sensitivity were balanced with values
close to 0.75. The highest threshold was found when
employing mouse data (tA=67%), which gave rise to perfect
specificity but this should be viewed with caution given the
limited data available (n=30). Rat and NHP showed thresh-
olds <50%, whilst the corresponding specificity for the rat was
lower than for any species investigated. In agreement with the
AUC values, NHP showed the highest specificity and sensitiv-
ity for its optimal threshold. Details of the drugs classified as
FN, FP, TN and TP according to the aforementioned thresh-
olds are shown in Tables SIII and SIV of the Supplementary
Material.
The NPV and PPV values showed an opposite relationship
to their corresponding sensitivities and specificities; this trend
was evident for all of the species and the overall dataset. All of
the corresponding PPV values were above 0.8, with the ex-
ception of the rat (0.72). Interestingly, NPV values were
similar for almost all of the species and the overall dataset;
however, corresponding values were higher for NHP. The
analysis of the impact of the ratio between the cost of FP and
FN on the resulting thresholds showed a sigmoid like increase
on the threshold value when varying the ratio from 0.0025 to
20 (Fig. 5). However, in some regions the thresholds remained
invariant to changes in the FP/FN ratios.
Fig. 2 (a ) Pie chart of the distribution of the oral bioavailability data points employed for the analysis by species, mouse (n=30), rat (n=122), dog (n=125) and
non-human primates (NHP) (n=41). (b ) Venn diagram of the relationship between oral bioavailability data points for rat, dog and NHP. The area of the circles
represents the number of compounds with oral bioavailability data for both animal species and humans, the areas of the interception represents the number of
compounds with bioavailability data for more than one species.
Fig. 3 Averaged ROC curve for the human versus animal bioavailability
dataset for all the preclinical species (mouse, rat, dog and NHP) combined.
The dashed line corresponds to the line for random classification, AUC=0.79
for the overall dataset.
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Visual inspection of the plots in Fig. 6 led to alternative
animal thresholds at 28%, 54%, and 31% for rat, dog and
NHP, respectively (Table III). Even though specificity and
sensitivity were balanced for all the species, NPV and PPV
showed similar relationships to the previous analysis. Yet, the
alternative thresholds showed no improvement of the overall
predictability of animal data for the particular species as
compared with the former thresholds derived from the cost
analysis. Youden’s index ( J) values for alternative thresholds
were lower than the values achieved by the aforementioned
thresholds (Tables III and V).
ROC Analysis of the reduced dataset of compounds with
very low Fhuman was not possible for NHP due to the lack of
compounds. Analysis of dog data (n=11) showed that this
preclinical animal model cannot be applied to the categorical
prediction of very low bioavailability compounds since AUC
was not significantly different from the random classification
(data not shown). Nevertheless, for rat data (n=34) ROC
Fig. 4 Averaged ROC curves for the human versus animal bioavailability dataset by preclinical species. (a ) Mouse ROC curve, AUC=0.82; (b ) Rat ROC curve,
AUC=0.73; (c ) Dog ROC curve, AUC=0.80; (d) NHP ROC curve, AUC=0.96; Dashed line corresponds to the line for random classification.
Table II Area Under the ROC Curve for Animal Models





All 318 0.786 0.734 0.835 <0.0001
Mouse 30 0.819 0.613 0.936 <0.005
Rat 122 0.731 0.634 0.818 <0.0001
Dog 125 0.796 0.708 0.870 <0.0001
NHPc 41 0.963 0.871 0.992 <0.0001
a n , number of data points employed for the determination of the ROC curve
b determined by bootstrap (n=10000)
cNHP, non-human primates
Table III Cost Analysis Derived Optimal Thresholds for FAnimal and its
Corresponding Evaluation Metrics
Species Opt. tA (%) Specificity (95% CI)
a Sensitivity (95% CI)a J
All 47 0.82 (0.75, 0.88) 0.66 (0.59, 0.73) 0.48
Mouse 67 1.00 (1.00, 1.00) 0.67 (0.41, 0.86) 0.67
Rat 22 0.60 (0.46, 0.72) 0.77 (0.67, 0.86) 0.37
Dog 58 0.80 (0.67, 0.89) 0.70 (0.59, 0.80) 0.50
NHP 35 1.00 (1.00, 1.00) 0.84 (0.65, 0.96) 0.84
Opt. tA, optimal threshold for Fanimal; 95% CI, 95% confidence interval; J ,
Youden’s Index as per Eq. 5
a determined by bootstrap (n=10000)
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analysis was possible (Fig. 7) and the results showed that the rat
model provided a significantly improvement on the predictions
as compared to the random classification (AUC=0.77; 0.52–
0.91, 95% confidence interval (CI)). In this case, the threshold
for high/low Fanimal was 7.4% with a corresponding sensitivity
of 0.95(0.75–1.00, 95% CI) and specificity of 0.67(0.40–0.88,
95% CI), indicating that rat can be used for predictions of very
low values of human bioavailability predictions.
Provisional BDDCS classification was assigned to 29 of the
compounds in the dataset (Table SI in the Supplementary
Material). The majority of the compounds analysed were
classified as Class 1 (47%), followed by Classes 3 (24%), 2
(22%) and 4 (7%). The proportion of compounds classified as
BDDCSClass 1 to 4 for every category after the application of
the classification model (i.e., TP, FN, TN and FP) is repre-
sented in Fig. 8. The results from Fisher’s test showed no
significant difference (p value >0.05) between the overall
BDDCS class distribution (“Ini.” In Fig. 8) and the
distribution within each threshold model classes (FN, TP,
TN and FP) for any of the preclinical species.
DISCUSSION
Several groups have suggested that pointwise correlation of oral
bioavailability between preclinical species and human is almost
non-existent and, therefore, data from such studies in preclinical
species should be treated with caution if the intention is to predict
human oral bioavailability quantitatively (4,15,16,36). The cur-
rent study performed a systematic analysis of F animal data from
four different species, including 184 compounds across all
BDDCS classes. Rather than attempting to predict a particular
value for Fhuman employing Fanimal data, ROC analysis performed
here showed that the animal data can be employed for a cate-
gorical prediction of high or low human bioavailability. The area
under the ROC curve is representative of the probability of
correctly classifying Fhuman as high and low when employing
Fanimal data: in our analysis the probability was around 80%
which can be considered as a high value (30). Even thoughmouse
data showed similar performance, the reduced number of data
points employed in the analysis limit us from making any con-
clusions about the utility of this preclinical model for making this
type of prediction. On the contrary, the higher abundance of rat
and dog data during preclinical development stages was reflected
in the smother ROC curves built for those particular species and
the resulting high probabilities for a correct classification
employing those species. This finding is in contrast to previous
attempts to establish correlations between animal and human
oral bioavailability (10,13,15,16,37) .
Albeit with a much smaller sample size than rat and dog,
NHP showed the best performance of all the species with a
probability for a correct classification around 100%. The
results are consistent with previous findings for this particular
species from pointwise correlation analyses (13,16). However,
the cost and ethical implications on the use of NHP during
preclinical development will limit their use to later stages of
the drug development process.
The resulting thresholds for the cost analysis in rat, dog and
NHP are consistent with the correlation analysis performed by
Musther and co-workers (16). Rat and NHP proved to be
underpredictive of human oral bioavailability and in the same
fashion the thresholds for high/low FAnimal were lower than
the threshold for high/low Fhuman. In contrast, threshold for
dog (58%) was relatively close to the human value, which is
consistent with the observed trend in the dog to neither
underpredict nor overpredict human oral bioavailability.
The model achieved high TPR (>0.70) and acceptable FPR
(≤0.40) employing the aforementioned thresholds for all the
preclinical species. The former suggests that it is unlikely to
have low oral bioavailability values in human when having
high oral bioavailability in any of the preclinical species.
Table IV Cost Analysis Derived Optimal Thresholds for FAnimal and its Cor-
responding PPV and NPV
Species Opt. tA (%) NPV PPV
All 47 0.64 0.84
Mouse 67 0.67 1.00
Rat 22 0.66 0.72
Dog 58 0.67 0.82
NHP 35 0.80 1.00
Opt. tA, optimal threshold for Fanimal; NPV, negative predictive value; PPV,
positive predictive value
Fig. 5 Impact of the FP/FN cost ratio on the determination of the optimal
thresholds by Eq. 4. Sky-blue line and circles, thresholds for the combined
dataset; Blue line and upper triangles, mouse thresholds; Red line and squares,
rat thresholds; Green line and lower triangles, dog thresholds; Yellow line and
diamonds, NHP thresholds.
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When we determined the optimal thresholds by an alter-
native method, the results were similar to the ones based on
cost analysis for rat, dog and NHP. In addition, the new
thresholds did not provide any significant improvement of
the ability to predict human high/low bioavailability from
animal data. The optimal thresholds may also be determined
by other alternative methods, such as the Euclidean distance
between the ROC curve and the hypothetical perfect classifi-
cation (e.g., point 0, 1 in the ROC space) (38). However, this
particular method does not take into account the nature of the
dataset unlike the ‘cost analysis’ determination based on Eq. 4.
Determination of the optimal thresholds according to Eq. 4
will depend upon the assigned net cost of FP and FN. In a
conservative fashion, a higher cost can be assigned to the FP
and the thresholds will move to a higher value and the oppo-
site will occur when assigning a higher net cost to FN. How-
ever, as shown in Fig. 5, the increase of the ratio follows a step
like increase in the thresholds (showing insensitive regions to
the assigned net cost ratios). For example a two-fold increase
on the net cost of a FP compared to the net cost of FN will
increase the threshold for both rat and dog, whereas a three-
fold increase will have the same impact on the resulting
thresholds as a tenfold increase. However, moving the thresh-
olds will affect the corresponding sensitivity and specificity
(Fig. 6) and thus the thresholds represent the best estimator
based on a balanced situation.
Even though rat predictions showed higher FPR than the
rest of the preclinical species, its convenience and availability
during preclinical development stages make it one the
commonest species employed to generate bioavailability data
for new drug candidates. Our threshold for rat predictions of
high/low Fhuman was 22%, consistent with similar thresholds
(F ≥20–30%) for the evaluation of rat Fanimal during drug
development published by different groups in the industrial
setting (19,20). In contrast to the current analysis, previously
proposed thresholds fail to provide any indication of the
expected range for human bioavailability and also the corre-
sponding TPR and FPR for the rat based predictions. From
the analysis of the reduced dataset for very low human oral
bioavailability (<20%), rat data showed the best performance
across species for prediction of Fhuman in this range, with the
probability for a correct prediction of high/low Fhuman of 77%.
Fig. 6 Sensitivity and specificity as a function of Fanimal thresholds for rat (a ), dog (b ) and NHP (c ). An increase on the thresholds will increase
the specificity but at the same time will decrease its sensitivity, the thresholds closer to the intercept between the two lines were chosen as
alternative thresholds. Red line and cross (-+-), specificity; Blue line and asterisk (-*-), sensitivity.










Rat 28 0.65 (0.51, 0.77) 0.67 (0.55, 0.77) 0.6 0.72 0.33
Dog 54 0.72 (0.58, 0.83) 0.73 (0.62, 0.83) 0.67 0.78 0.46
NHP 31 0.94 (0.67, 1.00) 0.88 (0.69, 0.96) 0.83 0.96 0.82
Alt. tA, alternative threshold for Fanimal;95% CI, 95% confidence interval;
NPV, negative predictive value; PPV, positive predictive value; J , Youden’s
Index as per Eq. 5
a determined by bootstrap (n=10000)
Fig. 7 ROC curve for rat predictions of very low human bioavailability
(Fhuman≤20%) dataset. The dashed line corresponds to the line of random
classification.
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The threshold (7.4%), in this case was close the human thresh-
old (10%), with a high TPR of 0.95 and with a small decrease
in the FPR to 0.33, confirming further the suitability of the rat
data for qualitative predictions of Fhuman during drug devel-
opment. Nevertheless, the shape of the ROC curve (Fig. 7)
suggests that it is necessary to obtain more data to validate this
conclusion.
The dataset employed for the generation of this predictive
model was based upon successful candidates and hence a
relatively high prevalence (58%) of compounds with high
Fhuman values was observed. It would be of interest to test this
model with a dataset reflective of the “true” drug development
process. However, we do not expect a high variation on the rat
threshold nor the resulting TNR and TPR , as our threshold
was in line with the ones employed in the development setting
and the latter are insensitive to the prevalence of high Fhuman
values (33).
ROC analysis for the evaluation of a predictive model of
human bioavailability has been applied before. Langdon and
Barret (39) developed a model for the prediction of oral bio-
availability in both rat and human based onQSAR and genetic
programing (GP). The evaluation of such a model was based on
the ability of the model to predict high (F ≥33%) and low
(F<33%) bioavailability in both human and rat. Interestingly
TNR and FNR were in agreement with results of our study.
BDDCS distributions of the drugs investigated in our anal-
ysis were in agreement with the observed distribution for
marketed drugs, where Classes 1 and 3 are the predominant
classes. Nevertheless, a different distribution can be expected
for new drug candidates, with a higher tendency for Class 2
and 3 drugs (23,25). However, our analysis on the outcome of
the classification model showed no clear tendency for any
particular BDDCS Class. One reason for this observation
can be attributed to the fact that BDDCS is a categorical tool
with no clear distinction between overall metabolism and first
pass metabolism. In addition, the binary nature of both BCS
and BDDCS does not account for the continuity of the prop-
erties employed within them- e.g., solubility, intestinal perme-
ability and/or extent of metabolism- which might be an issue
for the middle range of those properties and therefore affect-
ing the actual class distribution. Finally, interspecies differ-
ences in metabolic activity are not accounted for by the
existing BDDCS, and therefore the class distribution for a
particular drug could be different in a particular preclinical
species.
Even though our methodology was applied on animal
oral bioavailability data, a similar approach could be
employed to its constituents-fa , FG and FH-which might
be of more interest for some groups involved in preclinical
development. However, we suggest that a more mechanis-
tic approach should be attempted if the intention is to
quantitatively predict drug’s behaviour in man, taking in
consideration the physiological differences between the
preclinical species and humans in addition to drug’s in-
trinsic characteristic that can impact on drug’s oral bio-
availability and its individual components.
Fig. 8 Number of compounds and BDDCS class distribution for rat (a ), dog (b ) and NHP (c ) as a function of the outcome of the threshold based model. (d , e
and f) BDDCS class distribution for the outcome (in percentage of the outcome groups) for rat, dog and NHP, respectively. Ini., initial number of compounds; TP,
compounds classified as true positives, FN, compounds classified as false negatives; TN, compounds classified as true negatives; FP, compounds classified as false
positives.
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CONCLUSION
A new method for categorical prediction of high and low
human bioavailability from animal bioavailability data was
developed by employing ROC analysis. Oral bioavailability of
more than 50% in animals can successfully predict high oral
bioavailability in human, with high TPR and low FPR. A
similar scenario can be expected for bioavailability values
equal or greater than 22%, 58% and 35% in rat, dog and
NHP. Even though NHP was the best predictor of FHuman, rat
was shown to be the best predictor for low human oral
bioavailability, supporting the use of this animal model for
the Fhuman predictions in mid to early stages of drug develop-
ment. Thresholds proposed in the current study can be
employed in the pharmaceutical industry as part of the tool
box of methods for making decisions related to planning
necessary studies during the development of new drug candi-
dates and lead selection.
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